Cargando…
Could SARS-CoV-2 cause tauopathy?
Autores principales: | Pratt, James, Lester, Evan, Parker, Roy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292136/ https://www.ncbi.nlm.nih.gov/pubmed/34146504 http://dx.doi.org/10.1016/S1474-4422(21)00168-X |
Ejemplares similares
-
Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?
por: Mouliou, Dimitra S., et al.
Publicado: (2022) -
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021) -
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
por: van Doremalen, Neeltje, et al.
Publicado: (2020) -
Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection
por: Stellini, Roberto, et al.
Publicado: (2021) -
Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation
por: Wang, Pei-Gang, et al.
Publicado: (2020)